
Inside the Orphan Drug Revolution
The Promise of Patient-Centered Biotechnology
James A. Geraghty(Author)
Cold Spring Harbor Laboratory Press,U.S.
Published on 20. September 2022
Book
Hardback
265 pages
978-1-62182-468-8 (ISBN)
Description
"There are thousands of diseases classed as "rare" because they afflict only a small number of people. These patient groups were long ignored by a pharmaceutical industry that judged them too small to provide a return on the investment needed to develop an effective remedy. Forty years ago, a revolution started that transformed the prospects of patients with rare diseases. This book is in part a history, with eyewitness accounts of advances as they occurred and portraits of the pioneering scientists and physicians, tireless activists, and visionary business leaders who made the revolution happen, and it tells deeply personal stories of patients and parents willing to risk new, untried therapies"--
More details
Language
English
Place of publication
New York
United States
Illustrations
Illustrations
Dimensions
Height: 237 mm
Width: 161 mm
Thickness: 25 mm
Weight
670 gr
ISBN-13
978-1-62182-468-8 (9781621824688)
Copyright in bibliographic data and cover images is held by Nielsen Book Services Limited or by the publishers or by their respective licensors: all rights reserved.
Schweitzer Classification
Person
A widely recognized leader in the rare disease field, Jim Geraghty has been a director or chair of seven NASDAQ-listed biotech companies. He's worked on orphan drugs for more than 40 years--as a strategy consultant, a CEO, a leader of pioneering international operations at Genzyme, and a venture entrepreneur. A former trustee of Harvard Medical School's renowned Joslin Diabetes Center, he's spoken before both houses of Congress, at the World Economic Forum, and at many other high-profile conferences. A Georgetown graduate with a masters in psychology from Penn and a law degree from Yale, he is a citizen of three countries and lives in Boston.